These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 10925331)

  • 81. Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Westerhout CM; Boersma E
    Expert Opin Drug Saf; 2003 Jan; 2(1):49-58. PubMed ID: 12904124
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
    Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH;
    J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451
    [No Abstract]   [Full Text] [Related]  

  • 83. Thrombocytopenia and glycoprotein IIb-IIIa receptor antagonists.
    Stiegler HM; Fischer Y; Steiner S
    Lancet; 1999 Apr; 353(9159):1185. PubMed ID: 10210005
    [No Abstract]   [Full Text] [Related]  

  • 84. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials.
    Sciahbasi A; Biondi-Zoccai G; Romagnoli E; Valgimigli M; Rasoul S; van't Hof A; Lioy E; Stone GW
    Int J Cardiol; 2012 Mar; 155(2):243-8. PubMed ID: 21035214
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage.
    Ali A; Hashem M; Rosman HS; Kazmouz G; Gardin JM; Schrieber TL
    J Invasive Cardiol; 2003 Apr; 15(4):186-8. PubMed ID: 12668843
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors.
    Blankenship JC
    Am Heart J; 1999 Oct; 138(4 Pt 2):287-96. PubMed ID: 10502234
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.
    Boersma E; Westerhout CM
    Curr Opin Investig Drugs; 2004 Mar; 5(3):313-9. PubMed ID: 15083598
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor.
    Sitges M; Villa FP
    Int J Cardiol; 1997 Dec; 62(3):269-71. PubMed ID: 9476687
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Profound thrombocytopenia associated with tirofiban: case report and review of literature.
    Patel S; Patel M; Din I; Reddy CV; Kassotis J
    Angiology; 2005; 56(3):351-5. PubMed ID: 15889207
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).
    Trivedi SM; Shani J; Hollander G
    J Invasive Cardiol; 2002 Jul; 14(7):423-5. PubMed ID: 12082199
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes.
    Chew DP; Roffi M; Topol EJ
    Prog Cardiovasc Dis; 2001; 44(3):195-206. PubMed ID: 11727277
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
    Bougie DW; Wilker PR; Wuitschick ED; Curtis BR; Malik M; Levine S; Lind RN; Pereira J; Aster RH
    Blood; 2002 Sep; 100(6):2071-6. PubMed ID: 12200368
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
    Januzzi JL; Cannon CP; Theroux P; Boden WE
    Am Heart J; 2003 Nov; 146(5):764-74. PubMed ID: 14597924
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors.
    Christopoulos CG
    Blood; 2003 Feb; 101(4):1655; author reply 1655. PubMed ID: 12560245
    [No Abstract]   [Full Text] [Related]  

  • 95. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors.
    Madan M; Berkowitz SD
    Am Heart J; 1999 Oct; 138(4 Pt 2):317-26. PubMed ID: 10502237
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia.
    Rao J; Mascarenhas DA
    J Invasive Cardiol; 2001 Jun; 13(6):471-3. PubMed ID: 11385174
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.
    Ali A; Patil S; Grady KJ; Schreiber TL
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):181-4. PubMed ID: 10642769
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
    Taniuchi M; Kurz HI; Lasala JM
    Circulation; 2001 Jul; 104(5):539-43. PubMed ID: 11479250
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Risks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndrome.
    Latour-Pérez J
    Ann Pharmacother; 2001 Apr; 35(4):472-9. PubMed ID: 11302412
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Abciximab-induced delayed profound thrombocytopaenia.
    Jbara M; Bhogal S; Bajaj K; Chhabra L
    BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28576909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.